These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35483627)

  • 1. Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: A randomized controlled trial.
    Lai Y; Liang X; Fan H; Liu Y; Zheng L; Lu W; Sun Y; Huang D; Liu X; Zhang L; Zuo D; Shou Z; Tang Q; Wang Y; Li Z; Jiang Z; Zang S; Huang H; Tang Z; Li Q; Xiao J
    Complement Ther Med; 2022 Sep; 68():102839. PubMed ID: 35483627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial.
    Zheng L; Lu W; Xiao Q; Lai Y; Fan H; Sun Y; Huang D; Wang Y; Li Z; Jiang Z; Liu X; Zhang L; Zuo D; Shou Z; Tang Q; Huang H; Yang Y; Tang Z; Xiao J
    Sci Rep; 2021 Jul; 11(1):13894. PubMed ID: 34230526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tongxie Formula Reduces Symptoms of Irritable Bowel Syndrome.
    Fan H; Zheng L; Lai Y; Lu W; Yan Z; Xiao Q; Li B; Tang M; Huang D; Wang Y; Li Z; Mei Y; Jiang Z; Liu X; Tang Q; Zuo D; Ye J; Yang Y; Huang H; Tang Z; Xiao J;
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1724-1732. PubMed ID: 28634136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized, multiple-blind, placebo-controlled trial.
    Liang SB; Han M; Cheng HJ; Zhang QY; Zhang NW; Jia BY; Robinson N; Liu JP
    Trials; 2022 Mar; 23(1):226. PubMed ID: 35313933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study.
    Majeed M; Nagabhushanam K; Natarajan S; Sivakumar A; Ali F; Pande A; Majeed S; Karri SK
    Nutr J; 2016 Feb; 15():21. PubMed ID: 26922379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?-A randomized controlled trial.
    Wang Y; Fan H; Qi X; Lai Y; Yan Z; Li B; Tang M; Huang D; Li Z; Chen H; Zhu Q; Luo C; Chen X; Fen J; Jiang Z; Zheng L; Liu X; Tang Q; Zuo D; Ye J; Yang Y; Huang H; Tang Z; Lu W; Xiao J;
    Complement Ther Med; 2018 Oct; 40():95-105. PubMed ID: 30219477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Rao SSC; Heimanson Z; Pimentel M
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial.
    Li Q; Zhang BP; Huang SG; Ouyang WW; Xie JH; Wen ZH; Yang XB
    Trials; 2018 Jul; 19(1):367. PubMed ID: 29996882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Chen C; Tao C; Liu Z; Lu M; Pan Q; Zheng L; Li Q; Song Z; Fichna J
    Phytother Res; 2015 Nov; 29(11):1822-7. PubMed ID: 26400188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
    Howell CA; Kemppinen A; Allgar V; Dodd M; Knowles CH; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Gut; 2022 Dec; 71(12):2430-2438. PubMed ID: 35760493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing Re-evaluation of Tongxiening Granules () in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control Trial.
    Tang XD; Zhang SS; Hou XH; Li ZH; Chen SN; Feng PM; Yang XN; Li HZ; Wu JQ; Xia PJ; Yang XJ; Zhou HJ; Wang HY; Ai YW; Li K
    Chin J Integr Med; 2019 Dec; 25(12):887-894. PubMed ID: 31292845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial.
    Plasse TF; Barton G; Davidson E; Abramson D; Kalfus I; Fathi R; Raday G; Harris MS
    Am J Gastroenterol; 2020 Sep; 115(9):1466-1473. PubMed ID: 32639235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH; Kwon JG; Kim SK; Myung SJ; Park KS; Sohn CI; Rhee PL; Lee KJ; Lee OY; Jung HK; Jee SR; Jeen YT; Choi MG; Choi SC; Huh KC; Park H
    Neurogastroenterol Motil; 2015 May; 27(5):705-16. PubMed ID: 25809913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.